Zobrazeno 1 - 10
of 1 048
pro vyhledávání: '"Dasabuvir"'
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 6, Pp n/a-n/a (2022)
Abstract The immunosuppressive agents sirolimus and everolimus are sensitive CYP3A4 substrates with narrow therapeutic index. Ritonavir is a strong CYP3A inhibitor. A phase 1 study was conducted to evaluate the pharmacokinetics, safety, and tolerabil
Externí odkaz:
https://doaj.org/article/0dfb66dcc061425485027c359f9261f7
Autor:
Timsy Uppal, Kai Tuffo, Svetlana Khaiboullina, Sivani Reganti, Mark Pandori, Subhash C. Verma
Publikováno v:
Cell Insight, Vol 1, Iss 4, Pp 100046- (2022)
COVID-19 (Coronavirus Disease 2019) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus-2) continues to pose an international public health threat and thus far, has resulted in greater than 6.4 million deaths worldwide. Vaccines are c
Externí odkaz:
https://doaj.org/article/24ec9cd407bd498c81bcad367080804c
Publikováno v:
Journal of Virus Eradication, Vol 8, Iss 2, Pp 100074- (2022)
Coxsackievirus B3 (CVB3) infections may cause life-threatening diseases and have no approved specific treatment. Some promising approaches to treat viral diseases include drug repurposing and combination therapy. We have selected in this study dasabu
Externí odkaz:
https://doaj.org/article/ff14578c21684ebab826fa9868ffeef7
Autor:
Zsigmond Máté Kovács, József Óvári, Csaba Dienes, János Magyar, Tamás Bányász, Péter P. Nánási, Balázs Horváth, Adam Feher, Zoltan Varga, Norbert Szentandrássy
Publikováno v:
Pharmaceuticals, Vol 16, Iss 4, p 488 (2023)
ABT-333 (dasabuvir) is an antiviral agent used in hepatitis C treatment. The molecule, similarly to some inhibitors of hERG channels, responsible for the delayed rectifier potassium current (IKr), contains the methanesulfonamide group. Reduced IKr cu
Externí odkaz:
https://doaj.org/article/4969770aed67445f99b626397d6c0a4b
Autor:
Tsuyoshi Hayashi, Kosuke Murakami, Junki Hirano, Yoshiki Fujii, Yoko Yamaoka, Hirofumi Ohashi, Koichi Watashi, Mary K. Estes, Masamichi Muramatsu
Publikováno v:
mSphere, Vol 6, Iss 6 (2021)
ABSTRACT Human noroviruses (HuNoVs) are acute viral gastroenteritis pathogens that affect all age groups, yet no approved vaccines and drugs to treat HuNoV infection are available. In this study, we screened an antiviral compound library to identify
Externí odkaz:
https://doaj.org/article/a9c642e1f1e24c4bbfba755b253bef92
Publikováno v:
Scripta Medica, Vol 50, Iss 2, Pp 77-81 (2019)
Background: The purpose of this study was to assess the antiviral efficacy and safety of the direct-acting antivirals (DAAs) in therapy of chronic hepatitis C virus (HCV) infection. Methods: This real-life multi-centric study was performed at the Cli
Externí odkaz:
https://doaj.org/article/e5cb3fcdac7043a7b95a6833de97bc06
Publikováno v:
Kidney & Blood Pressure Research, Vol 43, Iss 2, Pp 594-605 (2018)
Background/Aims: Chronic hepatitis C (HCV) virus infection reactivates under immunosuppressive drugs and therefore has a negative impact on long-term survival of kidney transplant recipients. Treatment-induced clearance of hepatitis C virus (HCV) in
Externí odkaz:
https://doaj.org/article/eb14cc8f477340b582de8283135f6fa9
Autor:
Hussaini T
Publikováno v:
Hepatic Medicine: Evidence and Research, Vol 2016, Iss Issue 1, Pp 61-68 (2016)
Trana Hussaini1,2 1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; 2Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada Abstract: The treatment for chronic hepatitis C has been revolut
Externí odkaz:
https://doaj.org/article/5db086ab4bc344cea8a7abd9d0ae81d0
Publikováno v:
Remedium. :28-34
The World Health Organization reports that 3-4 mil. people are newly infected with hepatitis C virus per year, of which 70% will develop chronic HCV disease. Viral hepatitis is a significant burden on the state budget due to its prevalence among the
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 7, Iss 1, Pp 1-13 (2021)
Background Hepatitis C virus (HCV) is considered a worldwide health problem since it affects over 3% of the population and causes 300,000 fatalities per year. Chronic infection causes high morbidity and mortality in patients, leading to liver cirrhos